Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
A1L0T0
UPID:
HACL2_HUMAN
Alternative names:
Acetolactate synthase-like protein; IlvB-like protein
Alternative UPACC:
A1L0T0; O43341; Q96F08; Q99651; Q9BWN5; Q9UEB2
Background:
2-hydroxyacyl-CoA lyase 2, also known as Acetolactate synthase-like protein and IlvB-like protein, plays a crucial role in fatty acid alpha-oxidation within the endoplasmic reticulum. This process, dependent on thiamine pyrophosphate (TPP), involves the cleavage reaction crucial for the degradation pathway of phytosphingosine.
Therapeutic significance:
Understanding the role of 2-hydroxyacyl-CoA lyase 2 could open doors to potential therapeutic strategies.